
EP 265: How blood biomarkers are changing neurology diagnostics with Joe Volpe of Labcorp
Notas del episodio
This week on The Genetics Podcast, Patrick is joined by Dr. Joe Volpe, Executive Director, Scientific Strategy & Commercialization at Labcorp. They discuss how blood biomarkers like p-tau217 are changing Alzheimer’s diagnosis, which biomarkers are emerging in Parkinson’s disease and ALS, and what Labcorp’s real-world testing data reveals about how physicians use these tests.
Show Notes
0:00 Intro to The Genetics Podcast
00:58 Welcome to Joe
01:47 Joe’s career in HIV genetics and his move into neurology
06:35 Alzheimer’s blood biomarkers, beta amyloid, and the rise of p-tau217
11:04 Why p-tau217 works as a scalable Alzheimer’s blood test
12:35 How p-tau217 triages patients and what it can’t tell clinicians
14:08 APOE testing demand and why it predicts risk without being definitive
17:46 Where Alzheimer’s treatment and early detection go next, and what is still unknown
21:26 How Parkinson’s and ALS diagnostics are following the path Alzheimer’s took
24:09 Neurofilament light (NfL), peripherin, and DDC as emerging ALS and Parkinson’s biomarkers
27:04 Where DDC fits in Parkinson’s diagnosis compared with p-tau217
29:30 How Labcorp’s real-world testing data shows what NfL and p-tau217 are used for
34:27 How Labcorp decides which neurology biomarkers to launch and when
38:12 Future potential for migraine biomarkers that can guide treatment choices
41:07 Closing remarks